The top 5 OncLive TV videos of the week.
News|Videos|July 22, 2024
Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment
Author(s)Guillermo Garcia-Manero, MD
The aim of this study is to describe the demographic, clinical, and treatment characteristics of patients with LRMDS who were managed by physicians at Florida Cancer Specialists & Research Institute (FCS) and treated with ESAs, and to determine the proportion of LR-MDS patients who experience ESA failure and describe treatment patterns following ESA failure.
Advertisement
Advertisement
Related to this article
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
VIR-5500 Receives FDA Fast Track Designation in mCRPC
5